PFE - Pfizer Inc.
| Previous Close | 36.49 |
| Open | 36.39 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 36.27 - 36.69 |
| 52 Week Range | 31.67 - 39.43 |
| Volume | 15,784,274 |
| Avg. Volume | 24,886,462 |
| Market Cap | 217.302B |
| Beta | 0.95 |
| PE Ratio (TTM) | 10.39 |
| EPS (TTM) | 3.52 |
| Earnings Date | May 1, 2018 |
| Forward Dividend & Yield | 1.36 (3.74%) |
| Ex-Dividend Date | 2018-02-01 |
| 1y Target Est | 40.16 |
Reuters•24 minutes agoP&G's vitamin boost could signal more to come
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.
Reuters•1 hour agoP&G's vitamin boost could signal more to come
LONDON/CHICAGO (Reuters) - Procter & Gamble's $4.2 billion deal for Merck's vitamin and supplements business is the latest example of a major consumer company stocking up on health-related products. Just last month, cleaning product maker Clorox Co agreed to buy multivitamin company Nutranext for $700 million. The moves show how global consumer goods companies are looking to new, interesting areas to offset flagging growth in their core businesses.
- Business Wire•14 hours ago
Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders
Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 26, 2018. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Annual Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
- Zacks•14 hours ago
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
Market Realist•19 hours agoVyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
- Market Realist•yesterday
How Analysts View Tetraphase Pharmaceuticals in April 2018
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
- Market Realist•2 days ago
A Look at the Financial Performance of Spark Therapeutics
Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.
Market Realist•2 days agoAnalysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
- Market Realist•2 days ago
Analysts’ Ratings for Achaogen and Peers in April 2018
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
- Reuters•2 days ago
Canada seeks U.S. help to solve EpiPen shortage
Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.'s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States. EpiPens deliver a potentially lifesaving dose of the generic drug epinephrine via an automatic injector. Last week, Pfizer notified consumers in Canada and Britain that the device is in short supply due to manufacturing problems.
- Business Wire•2 days ago
A.M. Best Affirms Credit Ratings of Blue Whale Re Ltd.
A.M. Best has affirmed the Financial Strength Rating of A and the Long-Term Issuer Credit Rating of “a+” of Blue Whale Re Ltd. . The outlook of these Credit Ratings is stable.
InvestorPlace•2 days ago7 Stocks on a Long-Term Uptrend
Let’s call a spade a spade. Turnaround stocks are fun. They’re even more fun when you’re able to say you bought them at — or at least near — their low because you understood the underlying story better than most other investors did.
- InvestorPlace•2 days ago
5 Biotech IPOs to Watch in April
In many sectors, initial public offerings (IPOs) can generate a lot of buzz. After all, a new company is entering the markets. Investors want to know what the company does, how it operates and what potential it holds for future profits. For biotech IPOs, things are a bit different.
- Bloomberg•2 days ago
Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It
Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...
- InvestorPlace•3 days ago
AbbVie Inc. Is a Clear Value Play in Biotech Stocks
Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE:ABBV) are still down around 25 percent. Whether the stock was perfectly priced or investors wanted an excuse to lock in profits, ABBV stock still has tremendous value and growth ahead. On March 22, AbbVie reported disappointing Phase 2 data for its Rova-T study that sent its shares lower.
- Zacks•3 days ago
5 Drug Stocks Poised to Surpass on Earnings This Quarter
The outlook for the upcoming first-quarter results looks bright.
- Market Realist•3 days ago
Novartis’s 1Q18: Analysts Expect Revenue Growth
Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.
- Market Realist•3 days ago
Updates on AbbVie’s AndroGel, Lupron, and Kaletra
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
- Zacks•3 days ago
J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
- Market Realist•3 days ago
What Analysts Recommend for CymaBay Therapeutics
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
- Motley Fool•3 days ago
Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets
One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.
- American City Business Journals•4 days ago
Merck to move scientists and money toward promising cancer drug
“We’re going to put a lot of muscle behind this," Merck R&D chief Roger Perlmutter said.
- Market Realist•4 days ago
Analysts’ Recommendations for Johnson & Johnson on April 16
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
- Market Realist•4 days ago
Johnson & Johnson’s Revenue Estimates for 1Q18
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
- Market Realist•4 days ago
What to Expect from Johnson & Johnson’s 1Q18 Earnings
Johnson & Johnson's 1Q18 Earnings: What to Expect on April 17Johnson & Johnson’s estimates
